Literature DB >> 11433117

A program for treating olanzapine-related weight gain.

M P Ball1, V B Coons, R W Buchanan.   

Abstract

This study evaluated the effectiveness of a Weight Watchers program for patients with schizophrenia who had olanzapine-related weight gain and ascertained whether the severity of patients' psychiatric symptoms was correlated with the patients' success in losing weight. Seven men and four women who had been treated with olanzapine and who had gained at least 7 percent of their pretreatment body weight attended Weight Watchers meetings and were offered supervised exercise sessions. The patients' weight, body mass index, and psychiatric symptoms were assessed and were compared with those of a matched comparison group who did not attend the Weight Watchers program. Only the men experienced significant weight loss. No correlation was found between weight loss and exercise or change in psychiatric symptoms.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11433117     DOI: 10.1176/appi.ps.52.7.967

Source DB:  PubMed          Journal:  Psychiatr Serv        ISSN: 1075-2730            Impact factor:   3.084


  29 in total

1.  Effects of a multimodal lifestyle intervention on body mass index in patients with bipolar disorder: a randomized controlled trial.

Authors:  Kornelia Gillhoff; Jens Gaab; Luljeta Emini; Caroline Maroni; Joachim Tholuck; Waldemar Greil
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2010

2.  Exercise program adherence using a 5-kilometer (5K) event as an achievable goal in people with schizophrenia.

Authors:  Kimberly R Warren; M Patricia Ball; Stephanie Feldman; Fang Liu; Robert P McMahon; Deanna L Kelly
Journal:  Biol Res Nurs       Date:  2010-12-30       Impact factor: 2.522

3.  Side effects of atypical antipsychotics: a brief overview.

Authors:  Alp Uçok; Wolfgang Gaebel
Journal:  World Psychiatry       Date:  2008-02       Impact factor: 49.548

Review 4.  Lifestyle interventions for adults with serious mental illness: a systematic literature review.

Authors:  Leopoldo J Cabassa; Jerel M Ezell; Roberto Lewis-Fernández
Journal:  Psychiatr Serv       Date:  2010-08       Impact factor: 3.084

5.  Interventions for the metabolic syndrome in schizophrenia: a review.

Authors:  Evangelos Papanastasiou
Journal:  Ther Adv Endocrinol Metab       Date:  2012-10       Impact factor: 3.565

6.  Effect of a motivational group intervention upon exercise self efficacy and outcome expectations for exercise in Schizophrenia Spectrum Disorders (SSDs).

Authors:  Lora Humphrey Beebe; Kathlene Smith; Renee Burk; Olivera Dessieux; Dawn Velligan; Abbas Tavakoli; Clif Tennison
Journal:  J Am Psychiatr Nurses Assoc       Date:  2010-04       Impact factor: 2.385

Review 7.  Effectiveness and cost-effectiveness of lifestyle interventions on physical activity and eating habits in persons with severe mental disorders: a systematic review.

Authors:  Nick Verhaeghe; Jan De Maeseneer; Lea Maes; Cornelis Van Heeringen; Lieven Annemans
Journal:  Int J Behav Nutr Phys Act       Date:  2011-04-11       Impact factor: 6.457

8.  A pilot evaluation of the In SHAPE individualized health promotion intervention for adults with mental illness.

Authors:  Aricca D Van Citters; Sarah I Pratt; Kenneth Jue; Gail Williams; Patricia T Miller; Haiyi Xie; Stephen J Bartels
Journal:  Community Ment Health J       Date:  2009-12-10

9.  Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients.

Authors:  David C Henderson; Xiaoduo Fan; Paul M Copeland; Bikash Sharma; Christina P Borba; Ryan Boxill; Oliver Freudenreich; Corinne Cather; A Eden Evins; Donald C Goff
Journal:  J Clin Psychopharmacol       Date:  2009-04       Impact factor: 3.153

Review 10.  The effects of physical exercise in schizophrenia and affective disorders.

Authors:  Berend Malchow; Daniela Reich-Erkelenz; Viola Oertel-Knöchel; Katriona Keller; Alkomiet Hasan; Andrea Schmitt; Thomas W Scheewe; Wiepke Cahn; René S Kahn; Peter Falkai
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2013-07-20       Impact factor: 5.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.